Bill Anderson, Bayer CEO (Dia Dipasupil/Getty Images)
November 12, 2024 07:21 AM ESTUpdated November 13, 01:49 PM
Pharma

Bay­er not eye­ing new deals to ad­dress Xarel­to sales ero­sion

Ayisha Sharma

News Reporter

Bay­er re­it­er­at­ed its plans to ride out the gener­ic-dri­ven sales de­cline of its throm­bo­sis drug Xarel­to, as the com­pa­ny’s shares plum­met­ed to a record low …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times